Drugs / MOR106
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03689829 | Aug 2018 → Mar 2020 | atopic eczema | Lakefront Biotherapeutics NV | Terminated | No outcome recorded |
| Phase 1 | NCT02739009 | Apr 2016 → Aug 2017 | atopic eczema | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03864627 | Mar 2019 → Feb 2020 | atopic eczema | Lakefront Biotherapeutics NV | Terminated | No outcome recorded |
| Phase 2 | NCT03568071 | Apr 2018 → Mar 2020 | atopic eczema | Lakefront Biotherapeutics NV | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2018-02-17 | Lakefront Biotherapeutics NV | Results Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as late-breaking abstract at the American Academy of Dermatology (AAD) meeting in San Diego lakefrontbio.com ↗
In the study, MOR106 showed first signs of activity and durable responses and was generally well tolerated in AD patients. |
| 2017-09-27 | Lakefront Biotherapeutics NV | Results Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL-17C antibody MOR106 in atopic dermatitis patients lakefrontbio.com ↗
At the highest dose level, 5 out of 6 patients (83%) reached an improvement of at least 50% in atopic dermatitis symptoms (EASI-50) by week 4 |
| 2016-09-29 | Lakefront Biotherapeutics NV | Results MorphoSys and Galapagos Start First-In-Patient Dosing of IL-17C Antibody MOR106 in Atopic Dermatitis lakefrontbio.com ↗
We are delighted that MOR106 is now being investigated in patients after favorable safety results were shown in healthy volunteers. |
All press releases naming this drug 9 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MOR 106 | “The active pharmaceutical drug substance of MOR106 is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that binds with a high apparent affinity to human IL-17C.” NCT03568071 ↗ |
| Modality | Monoclonal antibody | “The active pharmaceutical drug substance of MOR106 is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that binds with a high apparent affinity to human IL-17C.” NCT03568071 ↗ |
| Route | Intravenous | “Single intravenous administration of MOR106” NCT02739009 ↗ |
| Target | IL17C | “binds with a high apparent affinity to human interleukin-17C (IL-17C)” NCT03689829 ↗ |